PCSK9 and melanoma: Moreover, PCSK9 inhibition was suggested as a promising way to enhance immune checkpoint therapy for melanoma (B16F10), triple-negative mouse breast cancer (4T1), and colorectal cancer (MC38 and CT26) [23].